Shots:

• Richter is eligible to receive up front along with milestones for development stages & is responsible for the development of the products & conduct both P-I & III studies along with supply finished commercial products in the US
• Hikma to get exclusive rights to commercialize in the US & is responsible for registering the products with the US FDA
• Denosumab is a human mAb & is used for the treatment of osteoporosis and fractures due to bone metastasis which is currently in P-I & III clinical studies. The product is marketed under two brands i.e., Prolia (60mg/ml solution for inj. in PFS) & Xgeva (120mg/1,7 ml solution for inj. in a vial)

­Ref: Hikma | Image: Hikma